CAS: 658084-23-2; (Z)-N-(3-Chlorophenyl)-3-((3,5-Dimethyl-4-(4-Methylpiperazine-1-Carbonyl)-1H-Pyrrol-2-yl)Methylene)-N-Methyl-2-Oxoindoline-5-Sulfonamide
该化合物是一种复杂的有机化合物,其特征是多功能组和结构多样性.该物质具有一种以其生物活动,特别是医药化学活动而闻名的全氟辛烷磺酸.一个氯联苯团体的存在表明它可能与生物目标发生相互作用,而其成分可能有助于其药用特性.该化合物的结构表明,它可能展示出"(3Z)"结构所描述的特定的立体化学化学特性,这可能影响其反应性和约束性.
- 英文名称(Z)-N-(3-Chlorophenyl)-3-((3,5-Dimethyl-4-(4-Methylpiperazine-1-Carbonyl)-1H-Pyrrol-2-yl)Methylene)-N-Methyl-2-Oxoindoline-5-Sulfonamide
- 中文名称N-(3-氯苯基)-N-甲基-3-[[3,5-二甲基-4-[(4-甲基哌嗪-1-基)羰基-1H-吡咯-2-基]亚甲基]-2-氧代-2,3-二氢-1H-吲哚-5-磺酰胺
- IUPAC名称(Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-(4-methylpiperazine-1-carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxoindoline-5-sulfonamide
- 其它别名(3z)-n-(3-chlorophenyl)-3-({3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1h-pyrrol-2-yl}methylene)-n-methyl-2-oxo-2,3-dihydro-1h-indole-5-sulfonamide; N-(3-Chlorophenyl)-N-methyl-3-[[3,5-dimethyl-4-[(4-methylpiperazin-1-yl)carbonyl]-1H-pyrrol-2-yl]methylene]-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide
- CAS编号658084-23-2
- MFCD编号:MFCD08276928
- EINECS号:636-258-1
- 分子式:C28H30ClN5O4S分子量:568.1
- 产品CID: 2489796
- 产品分类生物化工 → 抑制剂 → 蛋白酪氨酸激酶
物理性质
- 密度1.4±0.1 g/cm3
- pKa:11.62±0.20(预测)
- PSA:114.2
- LogP:2.15
- 折射率1.664
- 溶解性DMSO: 10 mg/mL At 60 °c
- 外观形态橙色粉末
- 储存条件2-8°C
- 产品应用该化合物用作癌症研究的选择性MET(C-MET)动脉抑制剂;它抑制依赖HGF的MET磷酸化,细胞扩散和迁移;诱发自发,吸附和G1细胞循环逮捕;抑制PI3K路径,禁止AKT,FKHR和GSK3Β的磷化;对C-MOT表象非小型细胞肺癌细胞和TPRMET变异型BAF3细胞进行有力的抗反扩散活动,对由BCR-ABL,TEL-JAK2,TEL-ABL或TEL/PDGFTER等其他致癌性强血脉动细胞转变的细胞没有重大影响.
MSDS等安全信息
欧盟法规
ECHA物质C&L通报合成工艺路线路线简述
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2902500000-苯乙烯
2902600000-乙苯 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-2019151483-A1
优先权日:2016-07-25
标 题:Methods of making 18f-labeled precursors and peptides, labeled c-met binding peptides, and methods of use thereof
发明人：BHATTACHARYYA FALGUNI; SWENSON ROLF; JAGODA ELAINE MARIE
权利人:US HEALTH
摘要:Described herein are novel methods for the synthesis of radiolabeling synthons such as [18F]fluoronicotinic acid-2,3,5,6-tetrafluorophenyl ester, and also methods of labeling a protein or peptide comprising a free amine group. A novel c-Met binding peptide, and imaging methods, are also described.
专利号:US-8232258-B2
优先权日:2001-04-27
标 题 :NK1 fragment of hepatocyte growth factor/scatter factor (HGF/SF) and variants thereof, and their use
发明人：GHERARDI ERMANNO; LIETHA DANIEL; BLUNDELL THOMAS LEON; CHIRGADZE DIMITRY YURIEVICH
权利人:GHERARDI ERMANNO; LIETHA DANIEL; BLUNDELL THOMAS LEON; CHIRGADZE DIMITRY YURIEVICH; CAMBRIDGE ENTPR LTD; MEDICAL RES COUNCIL
摘要:The present invention relates to variants of the NK1 fragment of the polypeptide growth factor HGF/SF which act as agonists of the MET receptor and their use. The agonists comprise at least one substitution at positions equivalent to 132, 134, 170 and 181 of full length HGF/SF and these substitutions provide a variant which shows scatter factor activity and induces DNA synthesis. In vivo the variants provide protection from liver damage in a model of acute liver failure.
专利号:US-2006178374-A1
优先权日:2004-08-26
标 题 :Aminoheteroaryl compounds as protein kinase inhibitors
发明人：CUI JINGRONG J; FUNK LEE A; JIA LEI; KUNG PEI-PEI; MENG JERRY J; NAMBU MITCHELL D; PAIRISH MASON A; SHEN HONG; TRAN-DUBE MICHELLE
权利人:AGOURON PHARMA
摘要:Aminoheteroaryl compounds are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.
专利号:CN-107365301-B
优先权日:2016-05-12
标 题:Synthesis method of crizotinib and preparation method of intermediate thereof
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Zhang Y, Li X, Yu Q, Lv X, Li C, Wang L, Liu Y, Wang Q, Yang Z, Fu X, Xiao R. Using network pharmacology to discover potential drugs for hypertrophic scars. Br J Dermatol. 2024 Sep 18;191(4):592-604. doi: 10.1093/bjd/ljae234. 17(5):806-814. doi: 10.18240/ijo.2024.05.03.
3: Wang Q, Li Y, Yuan H, Peng L, Dai Z, Sun Y, Liu R, Li W, Li J, Zhu C. Hypoxia preconditioning of human amniotic mesenchymal stem cells enhances proliferation and migration and promotes their homing via the HGF/C-MET signaling axis to augment the repair of acute liver failure. Tissue Cell. 2024 Apr;87:102326. doi: 10.1016/j.tice.2024.102326. Epub 2024 Feb 17. 24(1):43. doi: 10.1186/s12935-024-03235-2.
5: Lang L, Chen F, Li Y, Shay C, Yang F, Dan H, Chen ZG, Saba NF, Teng Y. Adaptive c-Met-PLXDC2 Signaling Axis Mediates Cancer Stem Cell Plasticity to Confer Radioresistance-associated Aggressiveness in Head and Neck Cancer. Cancer Res Commun. 2023 Apr 19;3(4):659-671. doi: 10.1158/2767-9764.CRC-22-0289.
合成参考文献
参考文献:10.1186/1475-2867-13-15
摘要:Ju L, Zhou C. Association of integrin beta1 and c-MET in mediating EGFR TKI gefitinib resistance in non-small cell lung cancer. Cancer Cell International. 2013 Feb 13;13(1):15. doi: 10.1186/1475-2867-13-15.
📝 需求与反馈
尽可能描述清楚需求与问题信息
